Clinical Trial Update: LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating LEE011 (ribociclib) in combination with docetaxel and prednisone for metastatic castration-resistant prostate cancer has completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• LEE011 (ribociclib) (ribociclib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Rahul Aggarwal | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-31